中国宝安集团股份有限公司董事会： 2019年 6月27日，你公司股东大会完成了第十四届董事局、 第十届监事会的换届选举。根据你公司《公司章程》，董事、监 事的任期均为三年，你公司第十四届董事局、第十届监事会的任 期现均已届满。截至目前，你公司仍未完成董事局和监事会的换 届选举工作，也未披露董事局和监事会延期换届事项具体进展。 我部对上述事项表示关注。请你公司尽快完成董事局和监事 会的改选工作，及时披露相关工作进展，确保生产经营、信息披 露等工作的稳定性。同时，提醒你公司及全体董事、监事和高级 管理人员严格遵守《证券法》《公司法》等法律法规，以及本所 《股票上市规则》等规定，真实、准确、完整、及时、公平地履 行信息披露义务。 深 圳 证 券 交 易 所 关于对中国宝安集团股份有限公司的关注函 公司部关注函〔2023〕第 305 号 1 深圳证券交易所 上市公司管理二部 2023 年 9 月 7 日 2 特此函告 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 16,282,917,663.35, representing a 20.51% increase compared to CNY 13,511,408,089.55 in the same period last year[12]. - Net profit attributable to shareholders of the listed company was CNY 491,669,061.64, up 16.18% from CNY 423,195,842.67 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 23.22% to CNY 329,671,097.09 from CNY 429,373,017.46[12]. - Basic earnings per share increased to CNY 0.1906, reflecting a 16.15% rise from CNY 0.1641[12]. - The company achieved total operating revenue of 1,629,019.86 million CNY in the first half of 2023, a year-on-year increase of 20.39%[22]. - The company's net profit attributable to shareholders reached 49,166.91 million CNY, reflecting a growth of 16.18% compared to the same period last year[22]. Cash Flow and Financial Position - The net cash flow from operating activities was CNY 3,077,547,200.25, a significant increase of 1,511.35% compared to a negative cash flow of CNY 218,056,954.00 in the previous year[12]. - The company reported a significant decrease in short-term loans by 56.68% to ¥3,602,196,975.75, attributed to the repayment of maturing loans[32]. - Cash and cash equivalents at the end of the reporting period amounted to ¥8,473,488,440.74, representing 17.19% of total assets, a decrease of 2.91% from the previous year[37]. - The company's total liabilities reached RMB 29.49 billion, down from RMB 33.54 billion, indicating a reduction of about 12.1%[120]. - The company's equity attributable to shareholders increased to RMB 9.65 billion from RMB 9.14 billion, reflecting a growth of about 5.6%[120]. Investment and Subsidiaries - The company has established a comprehensive capital operation capability, integrating industrial and capital operations to support its expansion strategy[21]. - The subsidiary BetterRay reported sales revenue of 1,342,273.66 million CNY, a 31.59% increase, but net profit decreased by 7.69% to 84,728.08 million CNY due to high inventory clearance and price declines[24]. - The company has set up several new subsidiaries, including Indonesia Betterray New Energy Materials Co., Ltd., with no significant impact on overall operations[52]. Industry Focus and Strategy - The high-tech industry is a key focus for the company, aligning with national strategies to develop new energy materials and the new energy vehicle industry, which are expected to grow significantly[16]. - The company is committed to continuous technological innovation and upgrading its business model in the biopharmaceutical sector to enhance resource value[17]. - The company plans to enhance operational efficiency in real estate by focusing on inventory reduction and sales promotion strategies[18]. Environmental Compliance and Initiatives - The company is committed to adhering to various environmental protection laws and standards in its operations[61]. - The company has obtained pollution discharge permits for several subsidiaries, with validity extending to 2027 and beyond[62]. - The company achieved a sulfur dioxide emission of 71.06 tons per year, indicating a focus on reducing environmental impact[64]. - The company has established multiple industrial waste gas discharge outlets, with a total of 13 identified[64]. - Betterray New Materials Group invested approximately 51.58 million yuan in environmental monitoring, hazardous waste treatment, and maintenance of environmental protection facilities in the first half of 2023[73]. Legal Matters and Disputes - The company is involved in a lawsuit regarding a land lease agreement, with a claimed amount of RMB 7,999,200 and interest of RMB 16,353,100[85]. - The company has filed a lawsuit against Henan Guoneng Battery Co., Ltd. and Beijing Guoneng Battery Technology Co., Ltd. for overdue payments and interest amounting to CNY 201.80 million[86]. - The company is actively involved in the bankruptcy proceedings of Zhuzhou Watma Battery Co., Ltd., with ongoing claims for overdue payments[86]. Risk Management - The company has disclosed risk factors and corresponding measures in the management discussion and analysis section of the report[2]. - The company faces risks related to industry policies, technology replacement, and supply chain dynamics in its high-tech and biopharmaceutical sectors[53][54]. - The company is focusing on risk control and management improvement in the real estate sector, aiming to enhance sales capabilities and accelerate inventory turnover[56]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 202,752, with 10 shareholders holding more than 5% of the shares[103]. - The largest shareholder, Shenzhen Chengxing Investment Co., Ltd., holds 426,868,042 shares, accounting for 16.55% of the total shares[105]. - The company reported a total of CNY 2,516.26 million in actual guarantees during the reporting period[95].

上市公司2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：中国宝安集团股份有限公司 | 非经营性资金占 | | 占用方与上市公 | 上市公司核算 | 2023年初占用资金 | 2023年1-6月占用累 | 2023年1-6月占用资 | 2023年1-6月偿还累 | 2023年6月末占用资 | | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 用 | 资金占用方名称 | 司的关联关系 | 的会计科目 | 余额 | 计发生金额（不含 利息） | 金的利息（如有） | 计发生额 | 金余额 | 占用形成原因 | | | 现大股东及其附 | | | | | | | | | | | | 属企业 | | | | | | | | | | | | 小 计 | —— | —— | —— | | - | - | - | | —— | —— | | 前大股东及其附 | | | | | | | | | | | | 属企业 | | | | | | | | | | | | 小 计 | —— | —— | —— ...

二〇二三年八月二十八日 （1）未发现公司存在大股东及其关联方资金占用的现象。 （2）公司十分重视对外担保的控制，对符合规定的担保有专门的审批流程， 并有专人对担保事项进行实时跟踪。报告期内，公司对外担保按相关规定履行了 决策程序和信息披露义务，不存在违规对外担保的情况。截止 2023 年 6 月 30 日， 公司对外担保均处于受控状态，无逾期担保和涉及诉讼的担保，公司对外担保没 有损害公司及公司股东尤其是中小股东的合法权益。 独立董事：梁发贤、李瑶、徐志鸿 中国宝安集团股份有限公司独立董事 对关联方资金占用及对外担保情况的专项说明和独立意见 根据《上市公司治理准则》、《公司章程》及其他有关规定对公司 2023 年上 半年关联方资金占用及对外担保等事项进行了认真审核。 ...

证券代码：000009 证券简称：中国宝安 公告编号：2023-032 中国宝安集团股份有限公司 关于股东减持计划届满暨实施情况的公告 股东深圳市富安控股有限公司保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 本公司及董事局全体成员保证公告内容与信息披露义务人提供的信息一致。 减持股份来源：首次公开发行股票前获得的股份。 二、其他相关说明 1、本次减持计划符合《证券法》《上市公司股东、董监高减持股份的若干指 引》《深圳证券交易所上市公司股东及董事、监事、高级管理人员减持股份实施 细则》等相关法律、法规及规范性文件的规定。 2、截至 2023 年 8 月 16 日，富安公司减持计划时间区间届满，本次减持实 施情况与此前预披露的减持意向、承诺、减持计划一致。 三、备查文件 中国宝安集团股份有限公司（以下简称"本公司"或"中国宝安"）于 2023 年 8 月 16 日收到股东深圳市富安控股有限公司（以下简称"富安公司"）出具的 《关于股份减持计划届满暨实施情况的告知函》，富安公司委托本公司于 2023 年 4 月 19 日在巨潮资讯网披露了《关于持股 5%以上股东减持计划的预披 ...

中国宝安集团股份有限公司（以下简称"公司"或"中国宝安"）于 2021 年 8 月 18 日发行的中国宝安集团股份有限公司 2021 年面向合格投资者公开发行公 司债券（第一期）（以下简称"21 宝安 01"、"本期债券"、债券代码：149600） 至 2023 年 8 月 18 日将期满 2 年。根据公司本期债券《2021 年面向合格投资者 公开发行公司债券（第一期）募集说明书》及《2021 年面向合格投资者公开发行 公司债券（第一期）上市公告书》有关条款的规定，在本期债券的计息期限内， 每年付息一次，现将有关事宜公告如下： 一、本期债券基本情况 1、债券名称：中国宝安集团股份有限公司 2021 年面向合格投资者公开发行 公司债券（第一期）（本期债券简称为"21 宝安 01"，债券代码为"149600"） | 债券代码：149600 | 债券简称：21 | 宝安 | | --- | --- | --- | | 债券代码：148037 | 债券简称：22 宝安 | | | | 01 01 | | | | | 公告编号：2023-030 | | 证券代码：000009 | 证券简称：中国宝安 | | 中国宝安集 ...

二、股东累计质押股份情况 截至 2023 年 8 月 8 日，韶关高创累计质押股份情况如下： 证券代码：000009 证券简称：中国宝安 公告编号：2023-029 中国宝安集团股份有限公司 关于大股东股权质押的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 本公司于 2023 年 8 月 8 日收到大股东韶关市高创企业管理有限公司（下称 "韶关高创"）的通知，获悉韶关高创于 2023 年 8 月 7 日将其所持有本公司的 90,000,000 股股份质押给中信证券股份有限公司，具体事项如下： | 股东 | 是否为控股 股东或第一 | 本次质押 | 占其所 | 占公司 | 是否 | 是否为 | 质押 | | 质押 | | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 大股东及其 | 数量（股） | 持股份 | 总股本 | 为限 | 补充质押 | 起始日 | | 到期日 | | 质权人 | 用途 | | | 一致行 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥8,228,499,170.23, representing a 44.78% increase compared to ¥5,683,423,572.87 in the same period last year[3] - The net profit attributable to shareholders for Q1 2023 was ¥239,346,190.45, up 44.94% from ¥165,134,224.14 in the previous year[3] - The basic earnings per share for Q1 2023 was ¥0.0928, reflecting a 45.00% increase from ¥0.0640 in the same period last year[3] - The net profit for Q1 2023 was CNY 466,266,526.51, an increase from CNY 450,961,686.24 in the same period last year, representing a growth of approximately 3%[15] - The total revenue from operating activities reached CNY 8,474,847,685.66, compared to CNY 4,512,263,714.73 in Q1 2022, indicating a significant increase of about 88%[17] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥1,727,503,958.72, a significant increase of 464.39% compared to -¥474,078,022.77 in Q1 2022[3] - The cash and cash equivalents net increase for Q1 2023 was ¥1,036,730,692.66, a 267.47% rise from -¥619,058,999.24 in the same period last year[7] - The company's cash and cash equivalents at the end of Q1 2023 amount to ¥10,070,952,149.69, a decrease from ¥10,531,615,227.89 at the beginning of the year[11] - The cash flow from operating activities generated a net amount of CNY 1,727,503,958.72, a turnaround from a negative cash flow of CNY -474,078,022.77 in Q1 2022[17] - The company experienced a net cash outflow from investing activities of CNY -727,360,643.47, an improvement from CNY -1,619,628,525.05 in the previous year[18] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥51,389,870,782.13, a decrease of 1.73% from ¥52,293,310,406.08 at the end of the previous year[3] - Non-current liabilities totaled ¥10,687,425,012.07, an increase from ¥9,258,839,983.57 year-over-year[13] - The company's cash and cash equivalents decreased to ¥6,657,890,346.84 from ¥8,315,457,905.76, a decline of 20%[13] - Total current assets are reported at ¥33,509,545,238.03, down from ¥34,986,065,478.91 at the start of the year[11] - Accounts receivable stand at ¥6,067,883,624.75, compared to ¥6,372,524,173.95 at the beginning of the year, indicating a decrease[11] Shareholder Information - The total number of common shareholders at the end of the reporting period is 226,236, with the top 10 shareholders holding a combined 40.17% of shares[8] - The largest shareholder, Shenzhen Chengxing Investment Co., Ltd., holds 16.55% of shares, totaling 426,868,042 shares[8] - The total number of shares held by the largest three shareholders is 448,710,475, representing 17.40% of the total shares[9] Investment and Expenses - The company reported a significant increase in investment income of 287.32%, amounting to ¥276,739,569.40, compared to ¥71,450,432.04 in the previous year[6] - The company experienced a 56.63% increase in operating costs, totaling ¥6,703,674,818.06, compared to ¥4,279,926,891.25 in Q1 2022[6] - Research and development expenses rose to ¥312,568,379.95, compared to ¥254,263,898.68 in the previous year, marking an increase of 23%[14] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[10] - There is no indication of any mergers or acquisitions in the current financial report[10] - The total assets impairment loss for Q1 2023 was CNY -43,011,591.77, contrasting with a gain of CNY 3,545,680.11 in Q1 2022[15] - The company reported a total comprehensive income of CNY 443,624,965.03 for Q1 2023, slightly up from CNY 442,967,681.48 in the same quarter last year[16]

Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.35 CNY per 10 shares to all shareholders, based on a total of 2,579,213,965 shares[2]. - The company distributed a cash dividend of ¥0.35 per 10 shares, totaling ¥90,272,488.77, which represents 100% of the total profit distribution[114][115]. - The company reported a total distributable profit of ¥395,102,959.66 at the end of the reporting period[115]. Financial Performance - The company's operating revenue for 2022 was ¥31,998,720,906.66, representing an increase of 82.29% compared to ¥17,553,419,112.71 in 2021[12]. - The net profit attributable to shareholders for 2022 was ¥1,156,580,360.59, an increase of 11.68% from ¥1,035,599,088.75 in 2021[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥680,810,615.67, up 75.72% from ¥387,441,388.95 in 2021[12]. - The net cash flow from operating activities for 2022 was ¥290,476,146.61, a significant improvement from a negative cash flow of ¥279,272,690.50 in 2021, marking a 204.01% increase[12]. - The total assets at the end of 2022 were ¥52,293,310,406.08, a 41.05% increase from ¥37,073,195,202.73 at the end of 2021[13]. - The net assets attributable to shareholders at the end of 2022 were ¥9,133,813,548.67, reflecting a 14.17% increase from ¥8,000,289,198.35 at the end of 2021[13]. - The company achieved a weighted average return on equity of 13.49% in 2022, slightly down from 13.90% in 2021[12]. Business Operations and Strategy - The company reported significant changes in its business scope, including investments in new materials and high-tech industries since 2014[10]. - The company has undergone several changes in its business operations, including real estate development and modern biomedicine projects[10]. - The company is focused on high-tech industries, including new energy materials and electric vehicles, aligning with national strategic initiatives for industry upgrades[20]. - The company plans to continue developing new technologies and expanding its market presence in strategic emerging industries, enhancing its operational capabilities[20]. - The company aims to develop functional health products leveraging existing technology, brand, and channels, while continuously innovating and upgrading its business model[22]. Research and Development - The company reported a significant increase in R&D expenses, totaling ¥1,508,490,891.16, which is an 86.90% increase compared to ¥807,125,218.97 in 2021[49]. - The number of R&D personnel increased to 1,557 in 2022, up 24.86% from 1,247 in 2021[54]. - R&D investment amounted to ¥1,521,111,792.01 in 2022, representing an 87.36% increase from ¥811,884,198.00 in 2021[56]. - The proportion of R&D investment to operating revenue rose to 4.75% in 2022 from 4.63% in 2021, an increase of 0.12%[56]. Environmental Compliance - The company strictly adheres to environmental protection laws and industry standards in its production and operational activities[125]. - The company and its subsidiaries are classified as key pollutant discharging units by environmental protection authorities[125]. - The company has obtained pollution discharge permits for its subsidiaries, ensuring compliance with environmental regulations[126]. - The total COD emissions for 2022 were 0.038 tons, with ammonia nitrogen at 0.0001 tons and phosphate at 0.0005 tons[127]. - The company has implemented measures to ensure that emissions meet the required standards after treatment[128]. Governance and Management - The company maintains a governance structure compliant with legal regulations, ensuring independent operation without major shareholder interference[86]. - The company has established independent financial and operational systems, ensuring no asset misappropriation by major shareholders[86]. - The company has a diverse board with members holding various professional qualifications, including registered accountants and legal professionals[93]. - The company has maintained stability in its leadership with no reported changes in directors or senior management during the reporting period[90]. Market and Industry Challenges - The real estate market faced unprecedented challenges in 2022, but policies are being implemented to stabilize and support the sector[23]. - The biopharmaceutical sector is under pressure from regulatory changes and the need for new business development to ensure sustainable growth[81]. - The company faces risks related to industry policies, technological obsolescence, and supply chain dynamics, with measures in place to mitigate these risks[80]. Legal and Compliance Issues - The total amount involved in the lawsuit against Shenzhen Yuntong Logistics Co., Ltd. and others is approximately 670.72 million RMB, with a claim for full compensation of this amount[145]. - The court has taken preservation measures on assets valued at approximately 670.72 million RMB belonging to the defendants, but the lawsuit has not yet been concluded[145]. - There were no significant penalties or rectifications reported during the reporting period[147]. Shareholder Structure - The company has no controlling shareholder or actual controller since 2009, with the top two shareholders holding 8.34% and 6.95% respectively[10]. - The largest shareholder holds 16.04% of the company, with the second and third largest shareholders holding 15.04% and 5.92% respectively, indicating a diversified ownership structure[86]. - The total number of ordinary shareholders at the end of the reporting period was 226,073[165]. Financial Instruments and Debt Management - The company has issued a total of three bonds, with a total amount raised of CNY 2.05 billion, including CNY 1 billion for the 2017 bond, CNY 300 million for the 2021 bond, and CNY 750 million for the 2022 bond[174][176]. - The company has maintained its debt repayment mechanisms and plans without any changes during the reporting period, ensuring investor rights are protected[178]. - The company has not reported any overdue bonds during the reporting period, indicating a stable financial position[178]. Community Engagement and Social Responsibility - The company donated over 90 million yuan in total for social responsibility initiatives, including 15.6 million yuan worth of medicines to impoverished areas in 2022[138]. - The company organized 68 health events, benefiting over 110,000 community residents with free health check-ups[138]. - The company has committed to ongoing support for rural revitalization efforts, including cash donations and product purchases[138].